View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
July 31, 2019updated 25 Nov 2021 10:15am

Diffuse Large B-Cell Lymphoma: CAR-T Therapies have highest commercial potential

CART-T therapies for B-cell lymphoma shows high efficiency with strong commercial and clinical attributes.

By GlobalData Healthcare

The diffuse large B-cell lymphoma (DLBCL) landscape is diverse, containing 12 drugs that are aimed at a variety of targets, including CD20, CD19, CD79B, CD3, COX2, PKCB, and PI3K.

Lymphoma treatment

The figure below displays a competitive assessment of the marketed and late-stage pipeline drugs for DLBCL, the most common subtype of non-Hodgkin’s lymphoma. The drugs are scored according to both their clinical and commercial attractiveness.

Roche’s Rituxan (rituximab) with chemotherapy is the standard-of-care regimen against which other agents are compared. While Rituxan possesses the highest clinical efficacy, it no longer possesses the highest commercial potential, as there are now rituximab biosimilars available in the US, five major Western European markets, and Japan.

Therapies with the highest commercial potential in DLBCL are the chimeric antigen receptor T-cell (CAR-T) therapies: Gilead’s Yescarta, Novartis’ Kymriah, and Celgene’s pipeline therapy lisocabtagene maraleucel, which have demonstrated high efficacy.

Other agents, including Celgene’s Revlimid (lenalidomide), Roche’s Polivy (polatuzumab vedotin-piiq) TG Therapeutics’ ublituximab and umbralisib (also known as the U2 regimen), AbbVie and Johnson & Johnson’s Imbruvica, Teva’s Treanda (bendamustine), Morphosys’ tafasitamab, and Amgen’s Blincyto (blinatumomab), rank similarly in terms of commercial and clinical attributes.

The outlier is Denovo Biopharma’s enzastaurin, an agent that has previously failed to meet its primary endpoint in a Phase III trial in DLBCL.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU